Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk

Atherosclerosis

Volumn 223, Issue 1, 2012, Pages 230-234

  Gungor, Zeynep ^a   Anuurad, Erdembileg ^b   Enkhmaa, Byambaa ^b   Zhang, Wei ^b   Kim, Kyoungmi ^c   Berglund, Lars ^b,d  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

ApoE genotype; Coronary artery disease; Ethnicity; Inflammation

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN E4; C REACTIVE PROTEIN; FIBRINOGEN; PENTRAXIN 3; SERUM AMYLOID A;

ADULT; AFRICAN AMERICAN; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; VASCULITIS;

AFRICAN AMERICANS; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FIBRINOGEN; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PHENOTYPE; PHOSPHOLIPASES A2; RISK ASSESSMENT; RISK FACTORS; SERUM AMYLOID A PROTEIN; SERUM AMYLOID P-COMPONENT; UNITED STATES;

EID: 84863105080     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.04.021     Document Type: Article

References (29)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Eichner J.E., Dunn S.T., Perveen G., Thompson D.M., Stewart K.E., Stroehla B.C. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002, 155:487-495.
3. Gerdes L.U., Gerdes C., Kervinen K., Savolainen M., Klausen I.C., Hansen P.S., et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000, 101:1366-1371.
4. Anuurad E., Rubin J., Lu G., Pearson T.A., Holleran S., Ramakrishnan R., et al. Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. J Lipid Res 2006, 47:2475-2481.
5. Howard B.V., Gidding S.S., Liu K. Association of apolipoprotein E phenotype with plasma lipoproteins in African-American and white young adults. The CARDIA study. Coronary artery risk development in young adults. Am J Epidemiol 1998, 148:859-868.
6. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000, 1:507-537.
7. Eggertsen G., Tegelman R., Ericsson S., Angelin B., Berglund L. Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations. Clin Chem 1993, 39:2125-2129.
8. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation 2003, 107:499-511.
9. Latini R., Maggioni A.P., Peri G., Gonzini L., Lucci D., Mocarelli P., et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 110:2349-2354.
10. Eiriksdottir G., Aspelund T., Bjarnadottir K., Olafsdottir E., Gudnason V., Launer L.J., et al. Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykjavik Study. Atherosclerosis 2006, 186:222-224.
11. Grammer T.B., Hoffmann M.M., Renner W., Kleber M.E., Winkelmann B.R., Bohm B.O., et al. Apolipoprotein E genotypes, circulating C-reactive protein and angiographic coronary artery disease: the Ludwigshafen risk and cardiovascular health study. Atherosclerosis 2011, 215:487-493.
12. Davidson M.H., Corson M.A., Alberts M.J., Anderson J.L., Gorelick P.B., Jones P.H., et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008, 101:51F-57F.
13. Anuurad E., Ozturk Z., Enkhmaa B., Pearson T.A., Berglund L. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrinol Metab 2010, 95:2376-2383.
14. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990, 31:545-548.
15. Macy E.M., Hayes T.E., Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997, 43:52-58.
16. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957, 17:237-246.
17. Saougos V.G., Tambaki A.P., Kalogirou M., Kostapanos M., Gazi I.F., Wolfert R.L., et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007, 27:2236-2243.
18. Miller M., Mead L.A., Kwiterovich P.O., Pearson T.A. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol 1990, 65:1-5.
19. Lynch J.R., Tang W., Wang H., Vitek M.P., Bennett E.R., Sullivan P.M., et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003, 278:48529-48533.
20. Drabe N., Zund G., Grunenfelder J., Sprenger M., Hoerstrup S.P., Bestmann L., et al. Genetic predisposition in patients undergoing cardiopulmonary bypass surgery is associated with an increase of inflammatory cytokines. Eur J Cardiothorac Surg 2001, 20:609-613.
21. Mahley R.W., Nathan B.P., Pitas R.E. Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Ann N Y Acad Sci 1996, 777:139-145.
22. van den Elzen P., Garg S., Leon L., Brigl M., Leadbetter E.A., Gumperz J.E., et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005, 437:906-910.
23. Kuhlmann I., Minihane A.M., Huebbe P., Nebel A., Rimbach G. Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis 2010, 9:8.
24. Finch C.E., Morgan T.E. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res 2007, 4:185-189.
25. Jofre-Monseny L., Minihane A.M., Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 2008, 52:131-145.
26. Ballantyne C.M., Hoogeveen R.C., Bang H., Coresh J., Folsom A.R., Heiss G., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation 2004, 109:837-842.
27. Epps K.C., Wilensky R.L. Lp-PLA- a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med 2011, 269:94-106.
28. Enkhmaa B., Anuurad E., Zhang W., Pearson T.A., Berglund L. Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population. Atherosclerosis 2010, 211:526-530.
29. Murphy A.J., Akhtari M., Tolani S., Pagler T., Bijl N., Kuo C.L., et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 2011.